Food & Wine
BioSante Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Healthcare Conference
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Healthcare Conference being held in the New York Palace Hotel, New York City from September 12-15, 2010.
Stephen M. Simes, BioSantea™s president & chief executive officer, will speak on Tuesday, September 14 at 9:10 am ET. Mr. Simes will provide a status update on BioSantea™s lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante. A live audio webcast of Mr. Simesa™ remarks may be accessed at [ http://www.wsw.com/webcast/rrshq18/bpax ] and a replay will be available at the same link.
On the same day at 1 pm ET, Mr. Simes will participate on a panel titled: Structural Changes in the Capital Markets and Their Impact on Emerging Life Science Companies.
About the Rodman Healthcare Conference
The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.
Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrina" (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSantea™s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLooka"), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: [ www.biosantepharma.com ].